A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
Latest Information Update: 11 Dec 2023
Price :
$35 *
At a glance
- Drugs Umedaptanib pegol (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RAMEN
- Sponsors Ribomic
- 05 Dec 2023 According to a Ribomic media release, data from this study were published in the Eye.
- 05 Dec 2023 Results published in a Ribomic Media Release.
- 23 Mar 2022 Results published in the Ribomic Media Release.